Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 19:45:50 Source:travelViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift
Next:Cruise worker 'murders newborn son on board ship': Shocked co
You may also like
- Insider Q&A: CIA's chief technologist's cautious embrace of generative AI
- View of Harvest Across China
- Four More Chinese Irrigation Projects Designated World Heritage Structures
- China to Strengthen Home Visit Services for Elderly
- Young Boys seals 6th Swiss soccer league title in 7 years after rallying from firing coach Wicky
- China Reaches First Women's Basketball World Cup Semifinals in 28 Years
- 2022 China (Hainan) Int'l Tropical Agricultural Products Winter Trade Fair Kicks Off
- Four More Chinese Irrigation Projects Designated World Heritage Structures
- Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift